ResMed Inc. vs WD 40 Company — how do they compare? ResMed Inc. trades at $225 (market cap $32.61B), while WD 40 Company trades at $231.66 (market cap $3.13B). The key difference: ResMed Inc. is far larger — about 10.4× WD 40 Company's market cap, and WD 40 Company pays the higher dividend (1.75%). Which is the better fit depends on your goals.
| RMD | WDFC | |
|---|---|---|
Market Cap | $32.61B | $3.13B |
Sector | Health | Technology |
52-Week High | $293.73 | $264.91 |
52-Week Low | $182.82 | $187.52 |
Enterprise Value | $31.97B | $3.18B |
Dividend Yield | 1.17% | 1.75% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
WDFC trades at $232.3, down 0.94% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, but faces gross margin pressure from input costs. Revenue grew to $675 million in 2026, though net income slightly declined to $89 million. A dividend of $1.02 per share is scheduled for payment on July 31, 2026.
The outlook is mixed: solid brand strength and cash flow support stability, but high valuation (P/E 35.39) and margin pressures pose risks. Analyst sentiment is cautious with a hold-heavy consensus. Key opportunities include global market penetration, while risks involve cost inflation and competitive pressures.
Trailing returns across standard periods
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →